查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1726288

全球藥物基因體學技術市場：市場規模、佔有率、趨勢分析（按治療領域、技術和地區）、細分市場預測（2025-2030 年）

Pharmacogenomics Technology Market Size, Share & Trends Analysis Report By Therapeutic Area (Neurological Disorders, Cardiovascular Disease), By Technology (PCR, In-situ Hybridization), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

藥物基因體學技術市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，全球藥物基因體學技術市場預計到2030年將達到123.8億美元，2025年至2030年期間的複合年成長率為8.1%。

診斷學正在適應藥物基因體學檢測的興起，以及隨之而來的新生物療法。這些測試可以實現具有成本效益的治療，同時也為藥物開發過程增加了價值。與傳統方法相比，這些測試具有許多優勢，例如疾病風險預測、患者分層和治療反應監測，並有望成為藥物基因體學伴隨診斷市場取得重大進步的來源。

此外，藥物基因體學測試產品可幫助醫生個人化和最佳化患者治療方法。藥物基因體學和治療診斷學正在為整合醫學鋪平道路。這套專門的分子診斷測試的快速發展有助於改善疾病的即時治療評估。

然而，將基於藥物基因體學的測試早期整合到藥物開發時間表中並同時獲得核准所面臨的挑戰預計會阻礙成長。正確設計和執行臨床試驗以識別特定治療導致的個體和群體差異已成為治療診斷學成功的必要屬性。

藥物基因體學技術市場：概述

  • 到 2024 年，腫瘤學將佔據治療領域的主導地位，佔有率接近 40%。
  • 精準腫瘤學研究人員使用多種藥物以不同的組合來消除腫瘤，而不是簡單地減緩其生長。
  • 在治療診斷學技術方面，聚合酵素鏈鎖反應（PCR）佔據市場主導地位。 PCR技術因其諸多優點，被廣泛應用於臨床診斷，並成為該領域的重要技術。
  • 由於藥物開發商有將其產品與診斷技術結合的經濟獎勵，北美地區在藥物基因體學技術市場佔據主導地位。
  • 由於企業尋求利用尚未開發的商業機會，預計亞太地區將在預測期內見證最快的成長。
  • 藥物基因組學技術市場的主要企業包括 QIAGEN、GE HealthCare、安捷倫科技公司、F. Hoffmann-La Roche Ltd.、FOUNDATION MEDICINE, INC.、Oxford 藥物基因體學 Technologies plc.、Twist Bioscience、賽默飛世瑞爾科技公司、Leica Biosystems Nusslo Technologies plc.、Twist Bioscience、賽默飛世瑞爾科技公司、Leica Biosystems Nussloch GmB。
  • FOUNDATION MEDICINE, INC. 於 2024 年 11 月宣布，美國食品藥物管理局(FDA) 已批准 FoundationOne Liquid CDx 作為合作夥伴診斷，用於識別患有 MET 外顯子 14 跳躍改變的非小細胞肺癌 (NSCLC) 患者，這些患者有核准接受 TEPMETKO（Erlotinib）治療。這種基於血液的測試將有助於有標靶治療決策，並透過藥物基因組學分析支持精準腫瘤學。

目錄

第1章 分析方法與範圍

第2章執行摘要

第3章藥物基因體學技術市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 藥物基因體學技術市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL分析

第4章藥物基因體學技術市場：按治療領域的估計和趨勢分析

  • 治療區域儀表板
  • 藥物基因體學技術市場：按治療領域進行的變異分析
  • 全球藥物基因體學技術市場：按治療領域分類的市場規模預測和趨勢分析（2018-2030）
  • 瘤
    • 市場估計與預測（2018-2030）
    • 肺癌
    • 乳癌
    • 大腸直腸癌
    • 子宮頸癌
    • 其他
  • 神經系統疾病
    • 市場估計與預測（2018-2030）
  • 心血管疾病
    • 市場估計與預測（2018-2030）
  • 免疫疾病
    • 市場估計與預測（2018-2030）
  • 感染疾病
    • 市場估計與預測（2018-2030）
  • 其他
    • 市場估計與預測（2018-2030）

第5章藥物基因體學技術市場：按技術進行的估計和趨勢分析

  • 特定於技術的儀表板
  • 藥物基因體學技術市場：依技術進行差異分析
  • 全球藥物基因體學技術市場：市場規模預測與技術趨勢分析（2018-2030）
  • PCR
  • 原位雜合反應
  • 免疫組織化學
  • 定序
  • 其他

第6章藥物基因體學技術市場：按地區估計和趨勢分析

  • 市場儀表板：按地區
  • 各地區市場佔有率分析（2024 年及 2030 年）
  • 藥物基因體學技術市場：按地區分類的關鍵要點
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要企業熱力圖分析（2024年）
  • 公司簡介
    • QIAGEN
    • GE HealthCare
    • Agilent Technologies, Inc.
    • F. Hoffmann-La Roche Ltd
    • FOUNDATION MEDICINE, INC
    • Thermo Fisher Scientific Inc.
    • Oxford Nanopore Technologies plc.
    • Twist Bioscience
    • Leica Biosystems Nussloch GmBH
    • Pfizer Inc
    • Abbott
Product Code: GVR-1-68038-940-1

Pharmacogenomics Technology Market Growth & Trends:

The global pharmacogenomics technology market is anticipated to reach USD 12.38 billion by 2030 and is anticipated to expand at a CAGR of 8.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Diagnostics is adapting to the rise of pharmacogenomic tests, which are followed by the addition of new biological treatments. These tests enable cost-effective treatment and also add value to the process of drug development. Advantages associated with the usage of these tests such as disease risk prediction, patient stratification, and therapeutic response monitoring over the traditional methods is anticipated to a significant source of progress in this pharmacogenomics companion diagnostics market.

In addition, pharmacogenomics testing products aid physicians in individualizing and optimization of the patient's therapeutic regimen. Pharmacogenomics and theranostics are paving the way for integrated medicine. Rapid evolution in this group of specialized molecular diagnostic tests is contributing to improvement for the assessment of real-time treatment of disease.

However, the presence of challenges pertaining to early integration of pharmacogenomic based testing into drug development timelines for gaining approval simultaneously is anticipated to impede growth. Proper designing and implementation of clinical trials in order to identify individual as well as population variations from a given therapy have become a necessary attribute for the success of theranostics.

Pharmacogenomics Technology Market Report Highlights:

  • Oncology dominated the therapeutic area segment with nearly 40% share in 2024, driven by the presence of a substantial number of products
  • Precision oncology researchers aim to use multiple medications in various combinations to eliminate tumors rather than merely slowing their growth
  • Polymerase Chain Reaction (PCR) dominated the market the with respect to technology for theranostics. The PCR technique is widely used in clinical diagnostics due to its numerous advantages, making it a key method in the field.
  • North American region dominates the pharmacogenomics technology market because of economic incentives for drug developers to pair their products with diagnostics
  • Asia Pacific market is projected to showcase the fastest growth over the forecast period as the companies are engaged in capturing untapped opportunities
  • Key players operating in the pharmacogenomics technology market include QIAGEN; GE HealthCare.; Agilent Technologies, Inc.; F. Hoffmann-La Roche Ltd; FOUNDATION MEDICINE, INC.; Oxford Nanopore Technologies plc.; Twist Bioscience.; Thermo Fisher Scientific Inc.; Leica Biosystems Nussloch GmBH; Pfizer Inc.; Abbott
  • In November 2024, FOUNDATION MEDICINE, INC. announced that the U.S. Food and Drug Administration (FDA) had approved FoundationOne Liquid CDx as a partner diagnostic to identify patients with MET exon 14 skipping alterations in non-small cell lung cancer (NSCLC) eligible for treatment with TEPMETKO(erlotinib). This blood-based test helps guide targeted therapy decisions, supporting precision oncology through pharmacogenomic profiling.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Therapeutic area
    • 1.2.2. Technology
    • 1.2.3. Regional Scope
    • 1.2.4. Estimates and Forecasts Timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Therapeutic area outlook
    • 2.2.2. Technology outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Pharmacogenomics Technology Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Pharmacogenomics Technology Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Pharmacogenomics Technology: Therapeutic Area Estimates & Trend Analysis

  • 4.1. Therapeutic Area Dashboard
  • 4.2. Pharmacogenomics Technology Market: Therapeutic Area Movement Analysis
  • 4.3. Global Pharmacogenomics Technology Market Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
  • 4.4. Oncology
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Lung Cancer
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Breast Cancer
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Colorectal Cancer
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Cervical Cancer
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.6. Others
      • 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Neurological Disorders
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Cardiovascular Disorders
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Immunological Disorders
    • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Infectious Diseases
    • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Pharmacogenomics Technology Market: Technology Estimates & Trend Analysis

  • 5.1. Technology Segment Dashboard
  • 5.2. Pharmacogenomics Technology Market: Technology Movement Analysis
  • 5.3. Global Pharmacogenomics Technology Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
  • 5.4. PCR
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. In-situ Hybridization
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Immunohistochemistry
    • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Sequencing
    • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Pharmacogenomics Technology Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Dashboard
  • 6.2. Regional Market Share Analysis, 2024 & 2030
  • 6.3. Pharmacogenomics Technology Market by Region: Key Takeaways
  • 6.4. North America
    • 6.4.1. U.S.
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Canada
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Mexico
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. UK
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Germany
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. France
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Italy
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.5. Spain
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Norway
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.7. Sweden
      • 6.5.7.1. Key country dynamics
      • 6.5.7.2. Regulatory framework/ reimbursement structure
      • 6.5.7.3. Competitive scenario
      • 6.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.8. Denmark
      • 6.5.8.1. Key country dynamics
      • 6.5.8.2. Regulatory framework/ reimbursement structure
      • 6.5.8.3. Competitive scenario
      • 6.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Japan
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. China
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. India
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. Australia
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Thailand
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Brazil
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Argentina
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. South Africa
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.2. Saudi Arabia
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.3. UAE
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/ reimbursement structure
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.4. Kuwait
      • 6.8.4.1. Key country dynamics
      • 6.8.4.2. Regulatory framework/ reimbursement structure
      • 6.8.4.3. Competitive scenario
      • 6.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. Key company heat map analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. QIAGEN
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. GE HealthCare
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Agilent Technologies, Inc.
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. F. Hoffmann-La Roche Ltd
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. FOUNDATION MEDICINE, INC
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Thermo Fisher Scientific Inc.
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Oxford Nanopore Technologies plc.
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Twist Bioscience
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Leica Biosystems Nussloch GmBH
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Pfizer Inc
      • 7.4.10.1. Company overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product benchmarking
      • 7.4.10.4. Strategic initiatives
    • 7.4.11. Abbott
      • 7.4.11.1. Company overview
      • 7.4.11.2. Financial performance
      • 7.4.11.3. Product benchmarking
      • 7.4.11.4. Strategic initiatives

List of Tables

  • Table 1. List of abbreviations
  • Table 2. Global pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 3. Global pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 4. Global pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 5. North America pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 6. North America pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 7. North America pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 8. U.S. laboratory pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 9. U.S. pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 10. U.S. pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 11. Canada pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 12. Canada pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 13. Canada pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 14. Mexico pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 15. Mexico pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 16. Mexico pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 17. Europe pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 18. Europe pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 19. Europe pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 20. Germany pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 21. Germany pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 22. Germany pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 23. UK pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 24. UK pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 25. UK pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 26. France pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 27. France pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 28. France pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 29. Italy pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 30. Italy pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 31. Italy pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 32. Spain pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 33. Spain pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 34. Spain pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 35. Denmark pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 36. Denmark pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 37. Denmark pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 38. Sweden pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 39. Sweden pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 40. Sweden pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 41. Norway pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 42. Norway laboratory proficiency testing market, by technology, 2018 - 2030 (USD Million)
  • Table 43. Norway pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 44. Asia Pacific pharmacogenomics technology market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 45. Asia Pacific pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 46. Asia Pacific pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 47. China pharmacogenomics technology market, therapeutic area, 2018 - 2030 (USD Million)
  • Table 48. China pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 49. China pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 50. Japan pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 51. Japan pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 52. Japan pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 53. India pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 54. India pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 55. India pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 56. South Korea pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 57. South Korea pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 58. South Korea pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 59. Australia pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 60. Australia pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 61. Australia pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 62. Thailand pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 63. Thailand pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 64. Thailand pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 65. Latin America pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 66. Latin America pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 67. Latin America pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 68. Brazil pharmacogenomics technology, therapeutic area, 2018 - 2030 (USD Million)
  • Table 69. Brazil pharmacogenomics technology, by technology, 2018 - 2030 (USD Million)
  • Table 70. Brazil pharmacogenomics technology, by region, 2018 - 2030 (USD Million)
  • Table 71. Argentina pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 72. Argentina pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 73. Argentina pharmacogenomics technology market, by end region, 2018 - 2030 (USD Million)
  • Table 74. MEA pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 75. MEA pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 76. MEA pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 77. South Africa pharmacogenomics technology testing market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 78. South Africa pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 79. South Africa pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 80. Saudi Arabia pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 81. Saudi Arabia pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 82. Saudi Arabia pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 83. UAE pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 84. UAE pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 85. UAE pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
  • Table 86. Kuwait pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 87. Kuwait pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
  • Table 88. Kuwait pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Pharmacogenomics technology: market outlook
  • Fig. 10 Pharmacogenomics technology: competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 Pharmacogenomics technology market driver impact
  • Fig. 16 Pharmacogenomics technology market restraint impact
  • Fig. 17 Pharmacogenomics technology market strategic initiatives analysis
  • Fig. 18 Pharmacogenomics technology market: Therapeutic area analysis
  • Fig. 19 Pharmacogenomics technology market: Therapeutic area outlook and key takeaways
  • Fig. 20 Oncology market estimates and forecast, 2018 - 2030
  • Fig. 21 Neurological disorders market estimates and forecast, 2018 - 2030
  • Fig. 22 Cardiovascular diseases market estimates and forecast, 2018 - 2030
  • Fig. 23 Immunological disorders market estimates and forecast, 2018 - 2030
  • Fig. 24 Infectious diseases market estimates and forecast, 2018 - 2030
  • Fig. 25 Others market estimates and forecast, 2018 - 2030
  • Fig. 26 Pharmacogenomics technology market: Technology movement analysis
  • Fig. 27 Pharmacogenomics technology market: Technology outlook and key takeaways
  • Fig. 28 PCR market estimates and forecasts, 2018 - 2030
  • Fig. 29 In-situ hybridization market estimates and forecasts, 2018 - 2030
  • Fig. 30 Immunohistochemistry market estimates and forecasts, 2018 - 2030
  • Fig. 31 Sequencing market estimates and forecasts, 2018 - 2030
  • Fig. 32 Others market estimates and forecasts, 2018 - 2030
  • Fig. 33 Global Pharmacogenomics technology market: Regional movement analysis
  • Fig. 34 Global Pharmacogenomics technology market: Regional outlook and key takeaways
  • Fig. 35 North America market estimates and forecasts, 2018 - 2030
  • Fig. 36 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 37 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 38 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 39 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 40 UK market estimates and forecasts, 2018 - 2030
  • Fig. 41 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 42 France market estimates and forecasts, 2018 - 2030
  • Fig. 43 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 44 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 45 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 46 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 47 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 48 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 49 China market estimates and forecasts, 2018 - 2030
  • Fig. 50 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 51 India market estimates and forecasts, 2018 - 2030
  • Fig. 52 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 53 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 54 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 55 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 56 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 57 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 58 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 59 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 60 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 61 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 62 Kuwait market estimates and forecasts, 2018 - 2030